about
Screening and Prevention of Hepatitis B Virus Reactivation During ChemotherapyAdenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution.Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin.Relationship of BK polyoma virus (BKV) in the urine with hemorrhagic cystitis and renal function in recipients of T Cell-depleted peripheral blood and cord blood stem cell transplantationsEchinacea purpurea (L.) Moench modulates human T-cell cytokine response.Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study.Echinacea purpurea aerial extract alters course of influenza infection in mice.Effect of linezolid on clinical severity and pulmonary cytokines in a murine model of influenza A and Staphylococcus aureus coinfectionHigher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versusHepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignanciesA phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulinIncidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant.Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006.Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies.Adenovirus Viremia in Adult CD34(+) Selected Hematopoietic Cell Transplant Recipients: Low Incidence and High Clinical Impact.Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis.Lymphangitic papules caused by Nocardia takedensisWork-up for infectious diarrhea after allogeneic hematopoietic stem cell transplantation: single specimen testing results in cost savings without compromising diagnostic yield.Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027.Transmission of Clostridium difficile During Hospitalization for Allogeneic Stem Cell Transplant.Cutaneous involvement of disseminated adenovirus infection in an allogeneic stem cell transplant recipient.Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin.Disseminated adenovirus infection in cancer patients presenting with focal pulmonary consolidationInfectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy.Brincidofovir for polyomavirus-associated nephropathy after allogeneic hematopoietic stem cell transplantation.Monitoring of cytomegalovirus viral loads by two molecular assays in whole-blood and plasma samples from hematopoietic stem cell transplant recipientsBacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis.Approach to adenovirus infections in the setting of hematopoietic cell transplantation.Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.Diagnosis of Extrapulmonary Legionellosis in Allogeneic Hematopoietic Cell Transplant Recipients by Direct 16S Ribosomal Ribonucleic Acid Sequencing and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34+ Selected Hematopoietic Cell Transplantation.Toxoplasma Encephalitis in Atypical Hosts at an Academic Cancer Center.Detection of human norovirus in intestinal biopsies from immunocompromised transplant patients.Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell Transplantation.Trends in invasive pneumococcal disease (IPD) in cancer patients after the introduction of 7-valent pneumococcal conjugate vaccine (PCV7): A 20-year longitudinal study at a major urban cancer center.CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.Severe influenza and S. aureus pneumonia: for whom the bell tolls?Mycobacterium haemophilum infection after alemtuzumab treatment.
P50
Q26775184-B8A8A8D0-3E33-4A36-A7AE-088E727BB603Q33726613-BF88BDC0-E2A4-4D5D-95FE-88DC944C68EAQ33897804-79DA0352-60DE-4C13-ABD5-2B76D7ECA4AFQ33905299-3FF61979-573E-4A41-B2E1-E78B11438BDAQ34074274-8C266BD9-90D8-4FF2-A010-8AE94401A49CQ34175284-478E1299-E5AC-4E3E-9034-4C45EEFF9A16Q34467036-C76337A1-408C-48B4-94B3-D470C283E449Q34616215-E7D4A4A5-4AA7-4D62-B002-17394222CAD1Q34714699-9D5B253D-6548-4782-8C9F-F12D00F2C0A7Q34980027-370A5CC6-FBD3-4425-A14F-13A8D01CB22EQ34981585-CE9AC71B-62E2-4953-A356-400CDE24974CQ35081168-9CC2D139-D0DD-4194-B731-6CD209870DF5Q35190671-E050593B-C9AC-4C59-86D1-636025AFE5A0Q35514288-2A31D4C8-AF47-481E-AB26-C4714D52011FQ35848794-CB8C7D33-48F7-4066-AEA4-C4DE782C6230Q36355144-B26F8B09-A575-4C5D-9DFA-A583B4A5E237Q36445556-8580DB40-BEB0-480B-B1F2-474E441D889FQ36540732-E00712BA-7EC6-4D0F-A51A-7A1D6BA83269Q36731633-9B3B9DB4-6BF8-450C-B188-DC62EA1229BDQ36826112-BD8FFDB3-6E8F-454E-B511-582D2CFDEAB4Q36856267-51100E62-FA8F-48D8-BF91-5AA4A8BB5F00Q36977948-5DCEF63D-570A-4FC0-8916-C4BD878AAB36Q37173562-790B0F9E-4D5C-4A95-A79A-9FFD16D1CAE2Q37220447-5106F8ED-F464-417E-9D25-DB1D3D0AD22DQ37546635-2A2183D4-7020-40C5-82E5-21F522210E3BQ37858836-E1E38DDF-2E6E-485F-A40B-F54916C0CBA3Q38323818-98ACF6FA-4EBD-41DF-A09F-95F826DE9973Q38388033-44E419E4-2CD7-4B73-B3EB-EDD74176B3BDQ39202357-3288FAF6-4A62-4BF3-8EAC-1737B29F4BBDQ39404605-2D9F1441-D6A2-4C16-8120-50EC7F585FFBQ39770863-D57C5010-6398-4A1B-B98A-A581CB67EF17Q40075202-09B82421-DCCE-4E2C-937A-65B610B99058Q40138389-CE29A83C-A01F-43F2-853C-B9305F3BCCDBQ40280329-2090BDA6-0161-433A-B482-60A41A37DC9BQ40614360-6DDAFB05-067D-402D-B6E5-A716A14FEE78Q40674993-5735C3CF-34A6-4988-9D2F-9292B2AB9B7AQ41987062-D415F6A5-D579-407E-9EE6-331F2FE4DFD7Q42246598-F24E7330-A3F4-4CC9-8D0F-58840E25933BQ42524654-39BBB0F6-C75A-4ABC-9D5E-4285BEF397BFQ43194264-EFB10A77-E25A-4455-8D0B-0F249F824F65
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Genovefa Anna Papanicolaou
@ast
Genovefa Anna Papanicolaou
@en
Genovefa Anna Papanicolaou
@es
Genovefa Anna Papanicolaou
@nl
Genovefa Anna Papanicolaou
@sl
type
label
Genovefa Anna Papanicolaou
@ast
Genovefa Anna Papanicolaou
@en
Genovefa Anna Papanicolaou
@es
Genovefa Anna Papanicolaou
@nl
Genovefa Anna Papanicolaou
@sl
prefLabel
Genovefa Anna Papanicolaou
@ast
Genovefa Anna Papanicolaou
@en
Genovefa Anna Papanicolaou
@es
Genovefa Anna Papanicolaou
@nl
Genovefa Anna Papanicolaou
@sl
P106
P21
P31
P496
0000-0002-2891-079X